Geoffrey Alilonu, MD
Nephrology · Northport, ALNPI 1144295221
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 574 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.
Across 574 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$2K
- AstraZeneca$1K
- Fresenius USA Marketing, Inc.$1K
- Amgen$973
- Akebia Therapeutics Inc$751
- Vifor Pharma, Inc.$519
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,98597%
- Education$2513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 220 | $1,515 |
| AstraZeneca(2 entities) | 62 | $1,164 |
| Fresenius USA Marketing, Inc. | 75 | $1,083 |
| Amgen(2 entities) | 45 | $973 |
| Akebia Therapeutics Inc | 32 | $751 |
| Vifor Pharma, Inc. | 31 | $519 |
| Otsuka America Pharmaceutical, Inc. | 22 | $436 |
| Travere Therapeutics, Inc. | 13 | $265 |
| GSK | 11 | $196 |
| Bayer | 10 | $172 |
| Novo Nordisk | 12 | $158 |
| Daiichi Sankyo Inc. | 7 | $151 |
| Calliditas Therapeutics US Inc. | 6 | $138 |
| Bard Peripheral Vascular, Inc. | 2 | $120 |
| Novartis | 4 | $100 |
| Renalytix AI, Inc. | 1 | $92 |
| Mallinckrodt Enterprises LLC | 4 | $77 |
| Ardelyx, Inc. | 3 | $70 |
| Aurinia Pharma U.S., Inc. | 3 | $61 |
| Shire North American Group Inc | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 2 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $19 |
| Nxstage Medical, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$8,236 in reported general payments places this provider in the 80th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 218 | $315,124 |
| FarxigaDapagliflozin Propanediol | 132 | $96,190 |
| VelphoroSucroferric Oxyhydroxide | 27 | $74,637 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $31,755 |
| LokelmaSodium Zirconium Cyclosilicate | 39 | $29,797 |
| JardianceEmpagliflozin | 49 | $27,829 |
| Paricalcitol | 204 | $26,199 |
| AuryxiaFerric Citrate | 20 | $24,825 |
| Sevelamer Carbonate | 173 | $23,167 |
| ProsolParenteral Amino Acid 20% No.1 | 46 | $13,206 |
| DapagliflozinDapagliflozin Propanediol | 12 | $5,442 |
| Cinacalcet Hcl | 45 | $2,711 |
| Midodrine Hcl | 37 | $2,495 |
| Losartan Potassium | 315 | $2,108 |
| Gentamicin Sulfate | 53 | $1,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $1,515 | $315,124218 claims |
| AstraZenecaFarxiga, Lokelma | $1,164 | $125,988171 claims |
| Fresenius USA Marketing, Inc.Velphoro | $1,083 | $74,63727 claims |
| Boehringer IngelheimJardiance | $19 | $27,82949 claims |
| Akebia Therapeutics IncAuryxia | $751 | $24,82520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 nephrology providers in Alabama.
Other nephrology in Northport
- Michael QuadriniHuntsville$323K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
- Phillip MadoniaAlabaster$165K
- Thomas OzbirnHomewood$133K
- David WarnockBirmingham$128K
- Jeffrey GlazeHomewood$98K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.